Sarepta slides further after it reverses course and says it will stop shipments of gene therapy

Sarepta Therapeutics announced Monday evening that it would stop shipments of its gene treatment per a request from the US Food and Drug Administration, a reversal from its earlier stance of doubling down on continuing to sell the drug, which sent shares tumbling.

The company said it would “voluntarily and temporarily pause all shipments” of Elevidys in the US starting Tuesday. The drug, which treats muscular dystrophy, has been linked to at leasts two deaths from liver failure.

Sarepta, which slipped Monday during normal trading hours after it said it wouldn’t stop selling Elevidys, fell another 8% in after-hours trading on the announcement reversing that stance. The stock is down 30% since June 18, when it was first reported that the FDA requested the company to stop selling the drug — which accounts for half of its revenue — in the US.

More Markets

See all Markets

Luke Kawa

Futures surge, oil tumbles after President Trump agrees to two-week ceasefire

S&P 500 futures rose 2%, WTI futures tumbled double digits.

President Trump Addresses The Nation On The Conflict In Iran

Tasha Matsumoto

Stocks eke out gain ahead of tonight’s deadline for Iran to reopen the Strait of Hormuz

Traders were jittery ahead of the looming deadline, while President Trump posted on Truth Social that “a whole civilization will die tonight” if an agreement is not reached.

Luke Kawa

Anthropic is releasing its new model to select companies to get a head start on cyber defense

Fortune reported that the Claude developer would be doing this in late March.

Co-founder and CEO of Anthropic, Dario Amodei

Luke Kawa

12h

Stocks sink and oil spikes as traders price in enduring, worsening Mideast war

Stocks and oil are building in more risk premium to deal with the perceived increased probability of a more drawn-out disruption to global energy supplies and shipments.

Matt Phillips12h

Samsung’s massive Q1 fails to lift Sandisk, other data center plays

Almost all memory stocks slipped Tuesday, despite getting a positive update on the massive flood of money pouring into the sector from the AI build-out, as the potential escalation of the US war with Iran Tuesday evening overshadowed Samsung’s blowout numbers.

Korean chip giant Samsung Electronics reported preliminary Q1 results showing operating profit up by 755% compared to Q1 2025, trouncing pretty elevated expectations for a gain of about 550%.

Samsung is the world’s largest producer of NAND and DRAM chips. Once considered low-value commodity inputs to tech products, NAND and DRAM prices have exploded over the last six months amid a hyperscaler scramble to secure chips that can manage the surfeit of data produced by AI.

The same dynamics have made memory plays like Sandisk, Western Digital, and Micron some of the best-performing stocks in the S&P 500 over the last 12 months.

But other than Seagate Technology Holdings, those stocks were down Tuesday as of 11:15 a.m. ET, as the surge in oil prices and ongoing war with Iran muted much of the AI data center trade excitement. Bellwethers like Nvidia and hyperscalers like Oracle and Meta were struggling early, as were data center input makers like Corning and Coherent, AI power plays like GE Vernova, Vertiv Holdings, and even hard-hat builders of the shells that house all those AI servers.

On the other hand, some so-called optical stocks — makers of fiber-optic connections that quickly shift data between users, hyperscalers, and all around data centers themselves — were up. Lumentum and Arista Networks, two popular optical stocks, were showing resilience.

Samsung flags eightfold jump in quarterly profit as AI chip demand pumps prices

The same dynamics have made memory plays like Sandisk, Western Digital, and Micron some of the best-performing stocks in the S&P 500 over the last 12 months.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.